Division of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health & Science University, Terwilliger Boulevard, Portland, OR 97239, USA.
Nat Rev Rheumatol. 2013 Sep;9(9):524-31. doi: 10.1038/nrrheum.2013.82. Epub 2013 Jun 25.
In modern times a relationship between tuberculosis (TB) and rheumatoid arthritis (RA) has been firmly recognized, and is primarily attributable to the immunosuppressive therapies used to treat RA. Whereas TB can complicate the successful management of RA, nontuberculous mycobacteria have now perhaps become as important as (if not more so than) TB in the setting of RA, and can represent an even greater challenge to the rheumatologist wishing to use immunosuppressive therapies. This article reviews our most recent understanding of the epidemiological and clinical aspects of mycobacterial disease as it relates to RA, and the existing and emerging immunosuppressive therapies used to treat this disease.
在现代，结核病 (TB) 和类风湿性关节炎 (RA) 之间的关系已得到明确确认，主要归因于用于治疗 RA 的免疫抑制疗法。尽管 TB 可能会影响 RA 的成功治疗，但非结核分枝杆菌现在可能与 TB 一样重要（如果不是更重要的话），并且对于希望使用免疫抑制疗法的风湿病学家来说，它们可能构成更大的挑战。本文回顾了我们对与 RA 相关的分枝杆菌病的流行病学和临床方面的最新理解，以及用于治疗这种疾病的现有和新兴免疫抑制疗法。
